StockData
Contineum Therapeutics, Inc. logo

Contineum Therapeutics, Inc. (CTNM) stock

CTNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30
$9.24−0.31 (-3.25%)

Close on Nov 18, 2026Market cap $347.62MP/E –Yield –

Contineum Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Contineum Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$66.38M. For fiscal 2025 it was -$68.06M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$68.06M–
FY2024Dec 31, 2024-$50.89M-416.6%
FY2023Dec 31, 2023$16.08M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$17.43M–
Q1 FY2026Mar 31, 2026-$16.90M–
Q4 FY2025Dec 31, 2025-$17.12M–
Q3 FY2025Sep 30, 2025-$14.93M–
Q2 FY2025Jun 30, 2025-$17.90M–
Q1 FY2025Mar 31, 2025-$18.11M–
Q4 FY2024Dec 31, 2024-$17.05M–
Q3 FY2024Sep 30, 2024-$12.97M–
Q2 FY2024Jun 30, 2024-$10.94M-128.1%
Q1 FY2024Mar 31, 2024-$9.93M–
Q4 FY2023Dec 31, 2023-$9.68M–
Q3 FY2023Sep 30, 2023-$8.07M–
Q2 FY2023Jun 30, 2023$38.94M–
Q1 FY2023Mar 31, 2023-$5.12M–

More Contineum Therapeutics figures

See a number that looks wrong?